Brief: Heron Therapeutics Reaffirms Availability And Ample Supply Of Cinvanti®, Sustol®, And Aponvie® As Alternatives During The Potential Shortage Of Intravenous Fluids
10/10/2024 21:12
Heron Therapeutics Inc HRTX.O :
* HERON THERAPEUTICS REAFFIRMS AVAILABILITY AND AMPLE SUPPLY
OF
CINVANTI®, SUSTOL®, AND APONVIE® AS ALTERNATIVES DURING THE
POTENTIAL SHORTAGE OF INTRAVENOUS FLUIDS
Source text for Eikon: ID:nPn4zyBX9a
Further company coverage: HRTX.O
Recent news on Heron Therapeutics
See all newsHeron Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Heron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlook
Heron Therapeutics Inc expected to post earnings of 1 cent a share - Earnings Preview
Brief: U.S. District Court Issues Decision Regarding CINVANTI Patents
Heron Therapeutics' Q1 revenue falls as oncology sales drop